Compare XP & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XP | KYMR |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 9.0B |
| IPO Year | 2019 | 2020 |
| Metric | XP | KYMR |
|---|---|---|
| Price | $13.12 | $115.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 24 |
| Target Price | $19.94 | ★ $145.22 |
| AVG Volume (30 Days) | ★ 17.8M | 882.9K |
| Earning Date | 11-16-2026 | 10-29-2026 |
| Dividend Yield | ★ 4.83% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,211,000.00 |
| Revenue This Year | $12.83 | $153.48 |
| Revenue Next Year | $11.88 | N/A |
| P/E Ratio | $11.42 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.48 | $63.69 |
| 52 Week High | $32.73 | $142.92 |
| Indicator | XP | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 29.48 | 40.58 |
| Support Level | N/A | $104.96 |
| Resistance Level | $17.12 | $119.89 |
| Average True Range (ATR) | 0.63 | 7.15 |
| MACD | 0.03 | -2.16 |
| Stochastic Oscillator | 4.34 | 1.47 |
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission. Geographically, the company derives maximum revenue from Brazil and also has its presence in other countries.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.